CAR-T cell therapy is a type of immunotherapy that uses a patient's own immune system in addition to gene engineering technology.
T cells, a type of immune cells, are collected from a patient's blood, and the T cells are genetically modified to produce artificial receptors on their surface called “chimeric antigen receptors (CARs)”. CARs are receptor proteins that allow the T cells to recognize a surface antigen on cancer cells. CAR-T cells are then grown until they number in the billions and infused to the patient after 10 days to two weeks of being cultured in a laboratory.
After the infusion, the T cells multiply in the patients’ body, and genetically enginieered CAR-T cells recognize surface protein antigens on cancer cells and begin to attack it as a target.
1. Augmentation of gene-engineered T cell function for appropriate expansion, accumulation, and inducible memory function to solid cancer
Business alliance in the development of novel T cell therapy platform for
Exploring novel target antigen
for CAR-T therapy
4. Process development to secure a stable supply of CAR-T